http://orcid.org/0000-0002-2370-2174
References
- Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2015;91:516–524.
- Schuster P, Gabriel E, Kuefferle B, et al. Reversal by physostigmine of clozapine-induced delirium. J Toxicol Clin Toxicol. 1977;10(4):437–441.
- Stellpflug SJ, Cole JB, Isaacson BA, et al. Massive atropine eye drop ingestion treated with high-dose physostigmine to avoid intubation. West J Emerg Med. 2012;13(1):77–79.
- Pratico C, Quattrone D, Lucanto T, et al. Drugs of anesthesia acting on central cholinergic system may cause post-operative cognitive dysfunction and delirium. Med Hypotheses. 2005;65:972–982.
- Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors Focus on newer generation compounds. Life Sci. 2000;68:29–39.
- Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;60(Suppl 10):5–14.
- Stille G, Hippius H. Kritische stellungnahme zum begriff der neuroleptika. Pharmacopsychiatry. 1971;4:182–191.
- Gross H, Langner E. Das wirkungsprofil eines chemisch neuartigen breitbandneuroleptikums der dibenzoazepingruppe. Wien Med Wosch. 1966;116:814.
- Zom S, Jones S, Ward K, et al. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol. 1994;269:R1–R2.
- Zeng X, LE F, Scarisbrick I, et al. Muscarinic m4 receptor agonism by atypical but not typical antipsychotics [abstract]. Soc Neurosci. 1995;21:1707.
- Rosenbaum C, Bird SB. Timing and frequency of physostigmine redosing for antimuscarinic toxicity. J Med Toxicol. 2010;6:386–392.
- Kleinwachter. Beobachtung uber die Wirkung des Calabar-Extracts gegen Atropin-Vergiftung. Berliner Klinische Wochenschrift. 1864;369–371.
- Nickalls RWD, Nickalls EA. The first use of physostigmine in the treatment of atropine poisoning. A translation of Kleinwachter’s paper entitled ‘Observations on the effect of Calabar bean extract as an antidote to atropine poisoning’. Anaesthesia. 1988;43:776–777.
- Teoh R, Page A, Hardern R. Physostigmine as treatment for severe CNS anticholinergic toxicity. Emerg Med J. 2001;18:412–415.
- Hammon K, DeMartino K. Postoperative delirium secondary to atropine premedication. Anesth Prog. 1985;32(3):107–108.
- Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 1999;35(4):374–380.
- Arens AM, Shah K, Al-Abri S, et al. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clin Toxicol (Phila). 2018;56:101–107.
- Watkins JW, Schwarz ES, Arroyo-Plasencia AM, et al. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11:179–184.
- Moore PW, Rasimas JJ, Donovan JW. Physostigmine is the antidote for anticholinergic syndrome. J Med Toxicol. 2015;11:159–160.
- Dart R, Borron S, Caravati EM, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2009;54:386–394.
- Rasimas JJ, Sachdeva KK, Donovan JW. Revival of an antidote: bedside experience with physostigmine. J Am Assoc Emerg Psychiatr. 2014;12:5–24.